Life with consequences of breast cancer: Pregnancy during and after endocrine therapies

Breast

Volumn 13, Issue 6, 2004, Pages 443-445

  Goldhirsch, Aron ^a,b,c   Gelber, Richard D ^d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c International Breast Cancer Study Group   (Switzerland)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CLOMIFENE CITRATE; CYTOTOXIC AGENT; DIETHYLSTILBESTROL; GONADORELIN DERIVATIVE; TAMOXIFEN;

AMENORRHEA; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NEWBORN DISEASE; OVARY FUNCTION; OVULATION INDUCTION; PREGNANCY; PREMENOPAUSE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; TERATOGENICITY;

EID: 10244260550     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2004.08.015     Document Type: Editorial

References (12)

1. A. Goldhirsch R.D. Gelber Breast Cancer in Young Women In: J.R. Harris M.E. Lippman M. Morrow C.K. Osborne editors Diseases of the Breast 3rd ed 2004 Williams & Wilkins Lippincott 1339-1349
2. M. Colleoni N. Rotmensz C. Robertson L. Orlando G. Viale G. Renne A. Luini P. Veronesi M. Intra R. Orecchia G. Catalano V. Galimberti F. Nolé G. Martinelli A. Goldhirsch Very young women (<35 years) with operable breast cancer: Features of disease at presentation Ann Oncol 13 2002 273-279
3. Colleoni M Gelber S Snyder R Holmberg SB Fey M Thuerlimann B Lindtner J Byrne M Mendiola C Coates AS International Breast Cancer Study Group (IBCSG), Bern, Switzerland (randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: First results of International Breast Cancer Study Group Trial 13-93. ASCO 2004 Abstract No: 532)
4. A. Goldhirsch W.C. Wood R.D. Gelber A.S. Coates B. Thürlimann H.J. Senn Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 17 2003 3357-3365
5. Barthelmes L Gateley CA. Tamoxifen and Pregnancy. Breast, doi: 10.1016/jobreast.2004.08.007
6. Bamigboye AA Morris J Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes Cochrane Database Syst Rev 2003 3 CD004271
7. C. Fabian L. Sternson M. El-Serafi L. Cain E. Hearne Clinical pharmacology of tamoxifen in patients with breast cancer: Correlation with clinical data Cancer 48 4 1981 876-882
8. E.A. Lien E. Solheim P.M. Ueland Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment Cancer Res 51 18 1991 4837-4844
9. A.M. Jimenez-Gordo E. Espinosa P. Zamora J. Feliu N. Rodriguez-Salas M. Gonzalez-Baron Pregnancy in a breast cancer patient treated with a LHRH analogue at ablative doses Breast 9 2 2000 110-112
10. M. Castiglione-Gertsch A. O'Neill K.N. Price A. Goldhirsch A.S. Coates M. Colleoni M.L. Nasi M. Bonetti R.D. Gelber International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial J Natl Cancer Inst 95 24 2003 1833-1846
11. L.A. Emens N.E. Davidson Adjuvant hormonal therapy for premenopausal women with breast cancer Clin Cancer Res 9 1 Pt 2 2003 486S-494S
12. M.F. Mitwally R.F. Casper Aromatase inhibitors in ovulation induction Semin Reprod Med 22 1 2004 61-78